Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.

Brierley CK, Staves J, Roberts C, Johnson H, Vyas P, Goodnough LT, Murphy MF.

Transfusion. 2019 Jun 10. doi: 10.1111/trf.15397. [Epub ahead of print]

PMID:
31183877
2.

Ultrastructural identification of CD9 positive extracellular vesicles released from human embryos and transported through the zona pellucida.

Vyas P, Balakier H, Librach CL.

Syst Biol Reprod Med. 2019 May 28:1-8. doi: 10.1080/19396368.2019.1619858. [Epub ahead of print]

PMID:
31136209
3.

A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.

Roos-Weil D, Decaudin C, Armand M, Della-Valle V, Diop MK, Ghamlouch H, Ropars V, Hérate C, Lara D, Durot E, Haddad R, Mylonas E, Damm F, Pflumio F, Stoilova B, Metzner M, Elemento O, Dessen P, Camara-Clayette V, Cosset FL, Verhoeyen E, Leblond V, Ribrag V, Cornillet-Lefebvre P, Rameau P, Azar N, Charlotte F, Morel P, Charbonnier JB, Vyas P, Mercher T, Aoufouchi S, Droin N, Guillouf C, Nguyen-Khac F, Bernard OA.

Cancer Discov. 2019 Jun;9(6):796-811. doi: 10.1158/2159-8290.CD-18-0873. Epub 2019 Apr 24.

PMID:
31018969
4.

Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.

Bahekar R, Dave B, Soman S, Patel D, Chopade R, Funde R, Kumar J, Sachchidanand S, Giri P, Chatterjee A, Mahapatra J, Vyas P, Ghoshdastidar K, Bandyopadhyay D, Desai RC.

Bioorg Med Chem Lett. 2019 Jun 1;29(11):1313-1319. doi: 10.1016/j.bmcl.2019.04.007. Epub 2019 Apr 4.

PMID:
30975623
5.

Characterization of transgenic mouse lines for labeling type I and type II afferent neurons in the cochlea.

Vyas P, Wu JS, Jimenez A, Glowatzki E, Fuchs PA.

Sci Rep. 2019 Apr 3;9(1):5549. doi: 10.1038/s41598-019-41770-5.

6.

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2019 Feb 28;9(3):28. doi: 10.1038/s41408-019-0190-z.

7.

Inclusion of non-target antigen in vaccination favors generation of OVA specific CD4 memory T cells.

MohanKrishnan A, Patel H, Bhurani V, Parmar R, Yadav N, Dave N, Rana S, Gupta S, Madariya J, Vyas P, Dalai SK.

Cell Immunol. 2019 Mar;337:1-14. doi: 10.1016/j.cellimm.2018.11.005. Epub 2018 Nov 19.

PMID:
30773218
8.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. [Epub ahead of print]

PMID:
30635634
9.

SCL/TAL1 cooperates with Polycomb RYBP-PRC1 to suppress alternative lineages in blood-fated cells.

Chagraoui H, Kristiansen MS, Ruiz JP, Serra-Barros A, Richter J, Hall-Ponselé E, Gray N, Waithe D, Clark K, Hublitz P, Repapi E, Otto G, Sopp P, Taylor S, Thongjuea S, Vyas P, Porcher C.

Nat Commun. 2018 Dec 18;9(1):5375. doi: 10.1038/s41467-018-07787-6.

10.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S.

Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.

11.

Understanding Spatial and Contextual Factors Influencing Intraregional Differences in Child Vaccination Coverage in Bangladesh.

Vyas P, Kim D, Adams A.

Asia Pac J Public Health. 2019 Jan;31(1):51-60. doi: 10.1177/1010539518813604. Epub 2018 Nov 30.

PMID:
30499306
12.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.

Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H.

Leukemia. 2018 Dec;32(12):2546-2557. doi: 10.1038/s41375-018-0257-z. Epub 2018 Oct 1.

13.

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J.

Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. Erratum in: Blood Cancer J. 2019 Feb 28;9(3):28.

14.

New Insights into the Role of DNA Shape on Its Recognition by p53 Proteins.

Golovenko D, Bräuning B, Vyas P, Haran TE, Rozenberg H, Shakked Z.

Structure. 2018 Sep 4;26(9):1237-1250.e6. doi: 10.1016/j.str.2018.06.006. Epub 2018 Jul 26.

PMID:
30057026
15.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P.

Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16.

PMID:
30013198
16.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, Boultwood J.

Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.

17.

Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.

Tunstall O, Bhatnagar N, James B, Norton A, O'Marcaigh AS, Watts T, Greenough A, Vyas P, Roberts I, Wright M; British Society for Haematology.

Br J Haematol. 2018 Jul;182(2):200-211. doi: 10.1111/bjh.15390. Epub 2018 Jun 19. No abstract available.

PMID:
29916557
18.

Voltage-Gated Calcium Influx Modifies Cholinergic Inhibition of Inner Hair Cells in the Immature Rat Cochlea.

Zachary S, Nowak N, Vyas P, Bonanni L, Fuchs PA.

J Neurosci. 2018 Jun 20;38(25):5677-5687. doi: 10.1523/JNEUROSCI.0230-18.2018. Epub 2018 May 22.

19.

Cross fused renal ectopia with associated renal cell carcinoma.

Vyas P, Campbell K, Blute M.

Urol Case Rep. 2018 Mar 1;18:70-72. doi: 10.1016/j.eucr.2018.02.014. eCollection 2018 May. No abstract available.

20.

Assessment of different pretreatment technologies for efficient bioconversion of lignocellulose to ethanol.

Singh JK, Vyas P, Dubey A, Upadhyaya CP, Kothari R, Tyagi VV, Kumar A.

Front Biosci (Schol Ed). 2018 Jun 1;10:350-371. Review.

PMID:
29772563
21.

From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.

Jakobsen NA, Vyas P.

Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s47-s53. doi: 10.7861/clinmedicine.18-2-s47.

22.

Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease.

Schlotter F, Halu A, Goto S, Blaser MC, Body SC, Lee LH, Higashi H, DeLaughter DM, Hutcheson JD, Vyas P, Pham T, Rogers MA, Sharma A, Seidman CE, Loscalzo J, Seidman JG, Aikawa M, Singh SA, Aikawa E.

Circulation. 2018 Jul 24;138(4):377-393. doi: 10.1161/CIRCULATIONAHA.117.032291.

PMID:
29588317
23.

Animal models of status epilepticus and temporal lobe epilepsy: a narrative review.

Nirwan N, Vyas P, Vohora D.

Rev Neurosci. 2018 Sep 25;29(7):757-770. doi: 10.1515/revneuro-2017-0086. Review.

PMID:
29565791
24.

Tectona grandis (teak) - A review on its phytochemical and therapeutic potential.

Vyas P, Yadav DK, Khandelwal P.

Nat Prod Res. 2019 Aug;33(16):2338-2354. doi: 10.1080/14786419.2018.1440217. Epub 2018 Mar 6.

PMID:
29506390
25.

Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic.

Agrawal K, Das V, Vyas P, Hajdúch M.

Pharmacol Ther. 2018 Aug;188:45-79. doi: 10.1016/j.pharmthera.2018.02.006. Epub 2018 Feb 15. Review.

26.

Opposing expression gradients of calcitonin-related polypeptide alpha (Calca/Cgrpα) and tyrosine hydroxylase (Th) in type II afferent neurons of the mouse cochlea.

Sherry Wu J, Vyas P, Glowatzki E, Fuchs PA.

J Comp Neurol. 2018 Apr 15;526(6):1073. doi: 10.1002/cne.24380. Epub 2018 Jan 7. No abstract available.

PMID:
29423998
27.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

28.

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C, Jeffries S, Walter C, Piechocki K, Timbs A, Danby R, Raghavan M, Peniket A, Griffiths M, Bacon A, Ward J, Wheatley K, Vyas P, Craddock C.

Blood Adv. 2016 Dec 14;1(3):193-204. doi: 10.1182/bloodadvances.2016000760. eCollection 2016 Dec 27.

29.

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia.

Kinstrie R, Karamitros D, Goardon N, Morrison H, Hamblin M, Robinson L, Clark RE, Copland M, Vyas P.

Blood Adv. 2016 Dec 14;1(3):160-169. doi: 10.1182/bloodadvances.2016000810. eCollection 2016 Dec 27.

30.

Biochemical Properties and Neuroprotective Effects of Compounds in Various Species of Berries.

Kelly E, Vyas P, Weber JT.

Molecules. 2017 Dec 22;23(1). pii: E26. doi: 10.3390/molecules23010026. Review.

31.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK.

J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5.

32.

Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.

Karamitros D, Stoilova B, Aboukhalil Z, Hamey F, Reinisch A, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, Pflumio F, Porcher C, Majeti R, Göttgens B, Vyas P.

Nat Immunol. 2018 Jan;19(1):85-97. doi: 10.1038/s41590-017-0001-2. Epub 2017 Nov 21.

33.

Understanding practice patterns of glaucoma sub-specialists in India.

Choudhari NS, Pathak-Ray V, Kaushik S, Vyas P, George R.

Int J Ophthalmol. 2017 Oct 18;10(10):1580-1585. doi: 10.18240/ijo.2017.10.16. eCollection 2017.

34.
35.

Biomass breakdown: A review on pretreatment, instrumentations and methods.

Vyas P, Kumar A, Singh S.

Front Biosci (Elite Ed). 2018 Jan 1;10:155-174. Review.

PMID:
28930611
36.

Diverse p53/DNA binding modes expand the repertoire of p53 response elements.

Vyas P, Beno I, Xi Z, Stein Y, Golovenko D, Kessler N, Rotter V, Shakked Z, Haran TE.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10624-10629. doi: 10.1073/pnas.1618005114. Epub 2017 Sep 14.

37.

Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.

Mettananda S, Fisher CA, Hay D, Badat M, Quek L, Clark K, Hublitz P, Downes D, Kerry J, Gosden M, Telenius J, Sloane-Stanley JA, Faustino P, Coelho A, Doondeea J, Usukhbayar B, Sopp P, Sharpe JA, Hughes JR, Vyas P, Gibbons RJ, Higgs DR.

Nat Commun. 2017 Sep 4;8(1):424. doi: 10.1038/s41467-017-00479-7.

38.

Separation of neural stem cells by whole cell membrane capacitance using dielectrophoresis.

Adams TNG, Jiang AYL, Vyas PD, Flanagan LA.

Methods. 2018 Jan 15;133:91-103. doi: 10.1016/j.ymeth.2017.08.016. Epub 2017 Aug 31. Review.

39.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96202. Epub 2017 Sep 1. No abstract available.

40.

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P.

Clin Cancer Res. 2017 Nov 1;23(21):6430-6440. doi: 10.1158/1078-0432.CCR-17-1423. Epub 2017 Aug 1.

41.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS.

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

42.

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, Marteyn B, Farnoud NR, de Botton S, Bernard OA, Wu B, Yen KE, Tallman MS, Papaemmanuil E, Penard-Lacronique V, Thakurta A, Vyas P, Levine RL.

Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.

43.

Study of Short and Intermediate Term Clinical Outcomes of Patients with Protected and Unprotected LMCA Stenting.

Vyas PM, Prajapati JS, Sahoo SS, Patel IV, Deshmukh JK, Patel C, Singhal R.

J Clin Diagn Res. 2017 Apr;11(4):OC29-OC33. doi: 10.7860/JCDR/2017/21821.9716. Epub 2017 Apr 1.

44.

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.

Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N, Jamieson L, Vyas P, Anderson K, Segerstolpe Å, Qian H, Olsson-Strömberg U, Mustjoki S, Sandberg R, Jacobsen SEW, Mead AJ.

Nat Med. 2017 Jun;23(6):692-702. doi: 10.1038/nm.4336. Epub 2017 May 15.

PMID:
28504724
45.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Jun 1;127(6):2206-2221. doi: 10.1172/JCI91363. Epub 2017 Apr 24. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3557.

46.

Retrospective comparison of the Low Risk Ankle Rules and the Ottawa Ankle Rules in a pediatric population.

Ellenbogen AL, Rice AL, Vyas P.

Am J Emerg Med. 2017 Sep;35(9):1262-1265. doi: 10.1016/j.ajem.2017.03.058. Epub 2017 Mar 22.

PMID:
28363615
47.

Pseudomonas aeruginosa as an Etiologic Agent of Nephrolithiasis in Deep Water Divers.

Bird VY, Chastain-Gross R, Sutkowski R, Bird VG, Vyas P, Joseph R.

J Endourol Case Rep. 2017 Jan 1;3(1):4-6. doi: 10.1089/cren.2016.0117. eCollection 2017.

48.

Prevalent practice patterns in glaucoma: Poll of Indian ophthalmologists at a national conference.

Choudhari NS, Pathak-Ray V, Kaushik S, Vyas P, George R.

Indian J Ophthalmol. 2016 Oct;64(10):715-721. doi: 10.4103/0301-4738.195004.

49.

Quantification of Calcified Particles in Human Valve Tissue Reveals Asymmetry of Calcific Aortic Valve Disease Development.

Yabusaki K, Hutcheson JD, Vyas P, Bertazzo S, Body SC, Aikawa M, Aikawa E.

Front Cardiovasc Med. 2016 Nov 4;3:44. eCollection 2016.

50.

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.

Desborough M, Hadjinicolaou AV, Chaimani A, Trivella M, Vyas P, Doree C, Hopewell S, Stanworth SJ, Estcourt LJ.

Cochrane Database Syst Rev. 2016 Oct 31;10:CD012055. Review.

Supplemental Content

Support Center